Wall Street analyst updates UnitedHealth stock after Buffett's $1.6 billion stake

Bank of America Securities maintained a 'Neutral' rating on UnitedHealth Group (UNH) while raising its price target to $325 from $290, representing a nearly 7% upside from its current $304 price. This adjustment is driven by Berkshire Hathaway's $1.6 billion investment and stronger peer multiples (17.1x from 15.3x), with potential for earnings recovery in 2027. However, BofA remains cautious due to limited near-term earnings visibility and unresolved uncertainties, including leadership changes, suspended guidance, and federal probes into Medicare Advantage billing, suggesting a risk of continued underperformance despite UNH's market leadership.

Analysis

Bank of America has maintained a 'Neutral' rating on UnitedHealth Group (UNH) while increasing its price target to $325 from $290, signaling a potential 7% upside from its current price. The upward revision is underpinned by two key factors: Berkshire Hathaway's recent $1.6 billion investment, which serves as a significant vote of confidence, and an expansion in peer valuation multiples to 17.1x from a previous 15.3x. Despite these positive catalysts and a long-term earnings recovery scenario projected for 2027, BofA's cautious stance stems from substantial near-term challenges. These include limited earnings visibility, suspended financial guidance, recent leadership changes, and ongoing federal probes into its Medicare Advantage billing practices. These unresolved issues create a tangible risk of continued stock underperformance over the next 12 months, making the timing of value realization the central question for investors, even as UNH retains its market leadership with over 8 million Medicare Advantage members and a growing Optum unit.

Key Decisions for Investors

• Long-term investors may view the current uncertainty and Berkshire Hathaway's entry as an opportunity, but must be prepared to tolerate potential near-term underperformance until there is more clarity on earnings.
• Investors with a shorter time horizon should remain cautious, as the combination of suspended guidance, leadership changes, and federal probes presents significant headwinds that could suppress stock performance in the coming year.
• Monitor for key catalysts such as the reinstatement of financial guidance or any resolution regarding the federal investigations, as these events are critical for re-rating the stock and realizing the projected upside.
• Given that the price target hike is partly based on peer multiple expansion to 17.1x, it is prudent to track the valuation of the broader managed care sector as a benchmark for UNH's relative value.